Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARES: PegIFN Add-on to Entecavir in HBeAg-positive Chronic Hepatitis B
NCT00877760Phase 4Completed
- Sponsor
- Foundation for Liver Research
- Start
- Aug 2009
- Primary completion
- Jul 2013
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 5
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2a in Chronic Hepatitis B (CHB) (2 arms), sponsored by Foundation for Liver Research. Primary endpoint: Combined presence of HBV DNA level < 200 IU/mL and HBeAg loss at 48 weeks. Started Aug 2009; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00877760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00877760.